Camonsertib + Radiation Therapy for Head and Neck Cancer

This trial tests a new treatment combination for individuals with recurrent or hard-to-treat head and neck cancer. The researchers aim to determine if camonsertib, a potential new drug, combined with a precise form of radiation therapy, can safely and effectively control cancer growth. The trial targets patients whose cancer has returned after prior treatment or cannot be surgically removed. Those with head and neck cancer that cannot be surgically removed and have already undergone radiation therapy might be suitable candidates. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new drug.

The trial does not specify if you must stop taking your current medications, but you cannot use strong CYP3A4/5 inhibitors and inducers, or strong P-gp and BCRP inhibitors while participating. It's important to discuss your current medications with the trial team to ensure there are no interactions.

Research has shown that camonsertib, when used alone, was safe in earlier studies. In one study involving 120 patients with various advanced cancers, camonsertib was administered alone and was generally well-tolerated. Patients experienced some side effects, but these were manageable. Another study tested camonsertib with a low dose of gemcitabine (a chemotherapy drug) and found this combination to be safe as well.

Researchers are excited about the combination of camonsertib and stereotactic body radiation therapy (SBRT) for head and neck cancer because it offers a unique approach to treatment. Unlike traditional treatments that may involve extensive surgery or long courses of radiation and chemotherapy, this combination targets cancer cells more precisely and may reduce treatment time. Camonsertib is an innovative oral drug that enhances the effects of radiation by interfering with cancer cell DNA repair processes, potentially increasing the effectiveness of SBRT. This approach could lead to more effective treatments with fewer side effects, offering new hope for patients with head and neck cancer.

Research has shown that camonsertib, when combined with radiation therapy, might help manage head and neck cancer. In this trial, participants will receive camonsertib alongside Stereotactic Body Radiation Therapy (SBRT). Early results suggest that camonsertib increases cancer cells' sensitivity to radiation, enhancing its effectiveness. In studies involving advanced solid tumors, camonsertib demonstrated potential in slowing tumor growth. This combined approach aims to target cancer cells more precisely while protecting healthy tissue. Initial clinical findings provide hope for improved outcomes in patients with recurring or difficult-to-remove head and neck cancers.¹²⁶⁷⁸